PE20121077A1 - Compuestos de pirrolo[2,3-d]pirimidina - Google Patents

Compuestos de pirrolo[2,3-d]pirimidina

Info

Publication number
PE20121077A1
PE20121077A1 PE2012000447A PE2012000447A PE20121077A1 PE 20121077 A1 PE20121077 A1 PE 20121077A1 PE 2012000447 A PE2012000447 A PE 2012000447A PE 2012000447 A PE2012000447 A PE 2012000447A PE 20121077 A1 PE20121077 A1 PE 20121077A1
Authority
PE
Peru
Prior art keywords
methyl
pyrrolo
pyrimidin
cyclohexyl
compounds
Prior art date
Application number
PE2012000447A
Other languages
English (en)
Inventor
Brad Alan Acker
Susan J Hartmann
Horng-Chih Huang
Eric Jon Jacobsen
Michele Ann Promo
Sergey Gregory Wolfson
Jin Xie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20121077A1 publication Critical patent/PE20121077A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA DE FORMULA (I) DONDE A ES UN ANILLO HETEROCICLILO TALES COMO PIPERIDINILO, PIRROLIDINILO, AZETIDINILO O PIPERAZINILO OPCIONALMENTE SUSTITUIDOS CON HALO, CARBOXI, CN, OXO, ALQUILO(C1-C8), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-(TRANS-4-{[(3-METOXIPIPERIDIN-1-IL)SULFONIL]METIL}CICLOHEXIL)-N-METIL-7H-PIRROLO[2,3-d]PIRIMIDIN-4-AMINA; (3R)-1-[({(1S,3R,4S)-3-METIL-4-[METIL(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)AMINO]-CICLOHEXIL}METIL)SULFONIL]PIPERIDIN-3-OL; {1-[({TRANS-4-[METIL(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)AMINO]CICLOHEXIL}METIL)-SULFONIL]PIPERIDIN-3-IL}METANOL; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE QUINASAS DE JANUS (JAK) SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER, ARTRITIS, DIABETES, LEUCEMIA, LUPUS
PE2012000447A 2009-10-15 2010-10-01 Compuestos de pirrolo[2,3-d]pirimidina PE20121077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25203909P 2009-10-15 2009-10-15

Publications (1)

Publication Number Publication Date
PE20121077A1 true PE20121077A1 (es) 2012-08-10

Family

ID=43413616

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000447A PE20121077A1 (es) 2009-10-15 2010-10-01 Compuestos de pirrolo[2,3-d]pirimidina

Country Status (28)

Country Link
US (1) US8633206B2 (es)
EP (1) EP2488524B1 (es)
JP (1) JP5629324B2 (es)
KR (1) KR20120083452A (es)
CN (1) CN102574860A (es)
AP (1) AP2012006192A0 (es)
AR (1) AR078635A1 (es)
AU (1) AU2010308028A1 (es)
CA (1) CA2776028C (es)
CL (1) CL2012000795A1 (es)
CO (1) CO6531451A2 (es)
CR (1) CR20120164A (es)
CU (1) CU20120059A7 (es)
DO (1) DOP2012000080A (es)
EA (1) EA201290147A1 (es)
EC (1) ECSP12011855A (es)
ES (1) ES2426407T3 (es)
IL (1) IL218802A0 (es)
IN (1) IN2012DN02577A (es)
MA (1) MA33670B1 (es)
MX (1) MX2012004379A (es)
NI (1) NI201200053A (es)
PE (1) PE20121077A1 (es)
TN (1) TN2012000146A1 (es)
TW (1) TWI398444B (es)
UY (1) UY32947A (es)
WO (1) WO2011045702A1 (es)
ZA (1) ZA201202718B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
MX2011009824A (es) 2009-03-23 2012-01-25 Glenmark Pharmaceuticals Sa Derivados de pirimidina-diona fusionados como moduladores del trpa1.
CN102361874A (zh) 2009-03-23 2012-02-22 格兰马克药品股份有限公司 作为trpa1调节剂的呋喃并嘧啶二酮衍生物
IN2012DN00720A (es) 2009-07-06 2015-06-19 Ontorii Inc
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
WO2011075334A1 (en) * 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
BR112014001244A2 (pt) 2011-07-19 2017-02-21 Wave Life Sciences Pte Ltd métodos para a síntese de ácidos nucléicos funcionalizados
CN105001226B (zh) 2011-08-12 2017-09-08 日产化学工业株式会社 三环杂环化合物和jak抑制剂
EP2872147B1 (en) 2012-07-13 2022-12-21 Wave Life Sciences Ltd. Method for making chiral oligonucleotides
EP2873674B1 (en) 2012-07-13 2020-05-06 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
BR112015000784A8 (pt) 2012-07-13 2018-04-03 Wave Life Sciences Japan Grupo auxiliar assimétrico
MY173845A (en) * 2012-07-17 2020-02-24 Glaxosmithkline Ip No 2 Ltd Indolecarbonitriles as selective androgen receptor modulators
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
US20160123982A1 (en) 2013-02-04 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
ES2755130T3 (es) 2013-02-08 2020-04-21 Nissan Chemical Corp Compuesto de pirrolopiridina tricíclico, e inhibidor de JAK
EA027879B1 (ru) * 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
HUE035333T2 (en) * 2013-05-02 2018-05-02 Hoffmann La Roche Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
KR20230152178A (ko) 2014-01-16 2023-11-02 웨이브 라이프 사이언시스 리미티드 키랄 디자인
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
AU2015260349B2 (en) 2014-05-14 2019-02-21 Nissan Chemical Industries, Ltd. Tricyclic compound and JAK inhibitor
ES2750655T3 (es) 2014-08-12 2020-03-26 Pfizer Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
CN108699072B (zh) * 2016-02-16 2021-02-26 硕腾服务有限责任公司 用于制备7h-吡咯并[2,3-d]嘧啶化合物的方法
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
DK3915989T3 (da) * 2019-01-30 2023-09-18 Felicamed Biotechnology Co Ltd Jak inhibitor and preparation method therefor
IL264854A (en) * 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
US20220380310A1 (en) * 2019-07-01 2022-12-01 Ligang Qian P2x7r antagonists
CA3152021A1 (en) * 2019-08-26 2021-03-04 Chemwerth, Inc. Substituted (7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino compounds useful as jak1 inhibitors
CN115246833A (zh) * 2021-04-27 2022-10-28 洛阳惠中兽药有限公司 一种奥拉替尼化合物及其中间体化合物的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
HUP0102574A3 (en) * 1998-06-19 2002-01-28 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds
NZ518884A (en) 1999-12-10 2004-02-27 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds
ATE423120T1 (de) 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
PL377791A1 (pl) 2002-11-21 2006-02-20 Pfizer Products Inc. Pochodne 3-aminopiperydyny i sposoby ich wytwarzania
AU2004268621C1 (en) * 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
EP1687309A1 (en) 2003-11-17 2006-08-09 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
US20070270588A1 (en) 2004-03-05 2007-11-22 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine Derivatives
CA2572331A1 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
AU2006254840B2 (en) 2005-06-08 2012-08-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
ATE540952T1 (de) 2005-07-29 2012-01-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese
NZ567133A (en) 2005-09-30 2011-07-29 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
US7855225B2 (en) * 2006-03-02 2010-12-21 Astellas Pharma Inc. 17βHSD type 5 inhibitor
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
WO2009115084A2 (de) 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
ES2467109T3 (es) * 2008-08-20 2014-06-11 Zoetis Llc Compuestos de pirrolo[2,3-d]pirimidina

Also Published As

Publication number Publication date
CL2012000795A1 (es) 2012-09-07
NI201200053A (es) 2012-08-09
EP2488524B1 (en) 2013-07-03
AR078635A1 (es) 2011-11-23
CR20120164A (es) 2012-11-07
ECSP12011855A (es) 2012-06-29
EA201290147A1 (ru) 2012-11-30
DOP2012000080A (es) 2012-06-15
KR20120083452A (ko) 2012-07-25
MA33670B1 (fr) 2012-10-01
US8633206B2 (en) 2014-01-21
CU20120059A7 (es) 2012-06-29
CN102574860A (zh) 2012-07-11
IL218802A0 (en) 2012-06-28
IN2012DN02577A (es) 2015-08-28
CA2776028C (en) 2015-12-01
TWI398444B (zh) 2013-06-11
UY32947A (es) 2011-05-31
JP5629324B2 (ja) 2014-11-19
CA2776028A1 (en) 2011-04-21
AP2012006192A0 (en) 2012-04-30
US20110136765A1 (en) 2011-06-09
TW201125866A (en) 2011-08-01
CO6531451A2 (es) 2012-09-28
ZA201202718B (en) 2012-12-27
WO2011045702A1 (en) 2011-04-21
MX2012004379A (es) 2012-06-01
JP2013508266A (ja) 2013-03-07
ES2426407T3 (es) 2013-10-23
EP2488524A1 (en) 2012-08-22
TN2012000146A1 (fr) 2013-09-19
AU2010308028A1 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
PE20121077A1 (es) Compuestos de pirrolo[2,3-d]pirimidina
AU2017290362B2 (en) Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
US20190211009A1 (en) Compounds and compositions as inhibitors of endosomal toll-like receptors
CL2008002184A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension pulmonar, osteoporosis, artritis, entre otras.
PE20090964A1 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
SG170783A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
EP3173415A3 (en) Activators of human pyruvate kinase
MX2009005863A (es) Procedimiento para la preparacion de compuestos heterociclicos sustituidos por fluorometilo.
UA102088C2 (ru) Производные n-азабициклических карбоксамидов, их получение и применение в терапии
PE20160691A1 (es) Nuevos derivados de triazolo[4,5-d]pirimidina
TN2011000245A1 (en) Organic compounds
NZ595825A (en) Antibody containing igg2 having amino acid mutation introduced therein
EA200601619A1 (ru) 5,6-диалкил-7-амино-триазолопиримидины, способ их получения и их применение для борьбы с патогенными грибами, а также содержащие их средства
PE20060274A1 (es) (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico
PE20121482A1 (es) Derivados de imidazopiridina como inhibidores de jak
PE20091493A1 (es) Inhibidores de quinasa de pirrolopirazina
GB0508318D0 (en) Organic compounds
EA018953B1 (ru) Ингибиторы пептиддеформилазы
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
NZ600305A (en) Mglu2 agonists
DE602004018630D1 (en) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
Canale et al. Solid-supported synthesis, molecular modeling, and biological activity of long-chain arylpiperazine derivatives with cyclic amino acid amide fragments as 5-HT7 and 5-HT1A receptor ligands
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
UY29821A1 (es) Derivados de 5,6-dihidropirazolo(3,4)(1,4)diazepin-4(1h)-ona, procesos de preparación de dichos derivados, composiciones farmacéuticas conteniéndolos y aplicaciones.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal